240 related articles for article (PubMed ID: 32318829)
1. Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.
Reville PK; Kadia T
Curr Treat Options Oncol; 2020 Apr; 21(4):34. PubMed ID: 32318829
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
3. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Heuser M; Mina A; Stein EM; Altman JK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
6. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.
Kirtonia A; Pandya G; Sethi G; Pandey AK; Das BC; Garg M
J Mol Med (Berl); 2020 Aug; 98(8):1069-1091. PubMed ID: 32620999
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
9. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
10. Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
Winer ES
Hematol Oncol Clin North Am; 2020 Apr; 34(2):449-463. PubMed ID: 32089222
[TBL] [Abstract][Full Text] [Related]
11. Precision medicine in acute myeloid leukemia: Hope, hype or both?
Prasad V; Gale RP
Leuk Res; 2016 Sep; 48():73-7. PubMed ID: 27497757
[TBL] [Abstract][Full Text] [Related]
12. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
13. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
14. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
Kadia TM; Ravandi F; Cortes J; Kantarjian H
JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
[TBL] [Abstract][Full Text] [Related]
15. Current status and trends in the diagnostics of AML and MDS.
Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
18. Are we ready for precision medicine in acute myeloid leukemia?
Roboz GJ
Clin Adv Hematol Oncol; 2016 Aug; 14(8):582-4. PubMed ID: 27487100
[No Abstract] [Full Text] [Related]
19. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.
Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U
Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
